The current study has clearly shown that the novel STAT3 degrader SD‐3615 exhibits much more potent activity than Stattic in decreasing the survival of a panel of human cell lines for glioma, in apoptotic induction of these cells and in inhibiting the growth of glioma xenografts and PDXs in vivo. Here, STAT3 is linked to central nervous system cancer.